At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Observer-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Safety and Immunogenicity of Different Formulations of Monovalent Influenza A/Hong Kong/125/2017-like (H7N9) Virus Vaccine With AS03 Adjuvant System, Given as a Two-dose Series to Adults 18 to 64 Years of Age and 65 Years of Age and Older
In Brief
A Phase 2 clinical trial evaluating FLU-Q-PAN H7N9 Formulation 1, FLU-Q-PAN H7N9 Formulation 2, and 4 other interventions for Influenza, Human. Completed, enrolled 833 participants across 8 sites.
Detailed Summary
Study to evaluate the safety and immunogenicity of H7N9 antigen in combination with full or half doses of AS03 adjuvant system in healthy adults.
Study Details
Timeline
Interventions
Participants received two doses of the FLU-Q-PAN H7N9 Formulation 1 vaccine by intramuscular injection in the non-dominant arm.
Participants received two doses of the FLU-Q-PAN H7N9 Formulation 2 vaccine by intramuscular injection in the non-dominant arm.
Participants received two doses of the FLU-Q-PAN H7N9 Formulation 3 vaccine by intramuscular injection in the non-dominant arm.
Participants received two doses of the AS03B adjuvant by intramuscular injection in the non-dominant arm.
Participants received two doses of the AS03A adjuvant by intramuscular injection in the non-dominant arm.
Participants received two doses of Placebo by intramuscular injection in the non-dominant arm.